secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001437749-26-015013
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q1 BRIUMVI US rev $194.8M; raises FY guidance to $885-900M
--------------------------------------------------------------------------

- Q1 2026 total global revenue approx $205M; BRIUMVI U.S. net product revenue $194.8M (+63% YoY).
- Net income $19.8M vs $5.1M YoY; product revenue $201.3M vs $119.7M YoY.
- Raises FY 2026 BRIUMVI U.S. net product revenue target to $885-900M; Q2 target ~$220M.
- Cash $572.8M at March 31, 2026; repurchased $100M of stock in Q1 at avg $29.28/share.
- Pipeline: ENHANCE Phase 3 data mid-2026; subcutaneous BRIUMVI data year-end 2026/Q1 2027; azer-cel data H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/0001437749-26-015013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926015013/tgtx20260227_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer